Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02988401 · ClinicalTrials.gov registry record · Phase 1
Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis
A Phase 1 study of Multiple Sclerosis (Relapsing Remitting) and Multiple Sclerosis, Secondary Progressive, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 1
- Development phase
- 105
- Enrollment target
- 1
- Study location
NCT02988401 is a Phase 1 study of Multiple Sclerosis (Relapsing Remitting) and Multiple Sclerosis, Secondary Progressive that has completed, run by Johns Hopkins University. The registered enrollment target is 105 participants, below the 559-participant average among 29 other Multiple Sclerosis (Relapsing Remitting) trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02988401, a Phase 1 study of Multiple Sclerosis (Relapsing Remitting) and Multiple Sclerosis, Secondary Progressive, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 105 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate if giving insulin that is administered in the nostrils (intranasal) is safe and tolerable for people with multiple sclerosis (MS). It is also being done to evaluate if intranasal insulin improves cognitive function in people with MS and to evaluate how it might be working.
Conditions Studied
Interventions
- DRUG Insulin
- DRUG Placebo (Sterile diluent)
Study Locations (1)
Maryland
- Johns Hopkins University School of Medicine - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2017-12-01 |
| Est. Completion | 2021-12-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02988401
The ClinicalTrials.gov registry entry for NCT02988401 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 559-participant average among 29 other Multiple Sclerosis (Relapsing Remitting) trials with a reported enrollment target (81% lower). The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Multiple Sclerosis (Relapsing Remitting) appearing as the primary indexed condition, and to 2 interventions - of which Insulin is the first listed.
NCT02988401 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT02988401 about?
NCT02988401 is a clinical study titled "Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis". This study will evaluate if giving insulin that is administered in the nostrils (intranasal) is safe and tolerable for people with multiple sclerosis (MS). It is also being done to evaluate if intranasal insulin improves cognitive function in people with MS and to evaluate how it might be working.
What is the current status of trial NCT02988401?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 105 participants. The study started on 2017-12-01. Estimated completion is 2021-12-17.
What conditions does trial NCT02988401 study?
This clinical trial studies the following conditions: Multiple Sclerosis (Relapsing Remitting), Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, Primary Progressive.
What interventions are being tested in trial NCT02988401?
The interventions under investigation include: Insulin (DRUG), Placebo (Sterile diluent) (DRUG).
Who is sponsoring clinical trial NCT02988401?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02988401 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis (Relapsing Remitting)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy
RECRUITING · Phase 1
-
Safety of RG2077 in Patients With Multiple Sclerosis
COMPLETED · Phase 1
-
Motor Learning of Fall Resistant Skills Through Slip and Trip Exposure in Multiple Sclerosis
RECRUITING · NA
-
Intermittent Hypoxia in Persons With Multiple Sclerosis
RECRUITING · NA
-
Treatment of Cognitive Deficits in Multiple Sclerosis With High-Definition Transcranial Direct Current Stimulation
RECRUITING · NA
-
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
RECRUITING · Phase 3
Explore more on PlainTrial
Multiple Sclerosis (Relapsing Remitting)
All registered trials for this condition
Multiple Sclerosis, Secondary Progressive
All registered trials for this condition
Maryland
All trials with a study site in Maryland
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.